The role of microparticles bearing active tissue factor in cancer and thrombosis: "The Bouillaud Study"

The role of microparticles bearing active tissue factor in cancer and thrombosis: "The Bouillaud Study" - Microparticles and tissue factor in cancer and thrombosis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32659

Enrollment

700

Registered

2008-12-17

Start date

2008-12-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer malignancy

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: patients diagnosed with carcinomas(epithelial tumors) of the gastrointestinal tract including colorectal, pancreatic,stomach and bowel. Patients with cancer of the genito-urinary tract (i.e prostate and renal tumours). Also patients with adeno-and squamous carcinomas of the lung, cancer of the ovaries and hematological malignancies.

Exclusion criteria

Exclusion criteria: pregnant women recent immobilization systemic (chemo)therapy for metastatic disease

Design outcomes

Primary

Measure	Time frame
Study variables; MP-TF activity, MP phenotypes, cytokines, FV Leiden, FII mutations, sTF and sP-selectin. We will compare the results of the study variables (see above) between the different cancer types and between patients and healthy volunteers. The level of MP-TF activity and MP phenotypes will also be compared with patients who did and did not developed thrombosis, patients who did and did not undergo a change in the stage of their disease and survival between the different groups of patients.	—

Measure

Time frame

Study variables; MP-TF activity, MP phenotypes, cytokines, FV Leiden, FII mutations, sTF and sP-selectin. We will compare the results of the study variables (see above) between the different cancer types and between patients and healthy volunteers. The level of MP-TF activity and MP phenotypes will also be compared with patients who did and did not developed thrombosis, patients who did and did not undergo a change in the stage of their disease and survival between the different groups of patients.

—

Secondary

Measure	Time frame
MP-TF activity, MP-phenotypes, FV Leiden and FII mutations in the controle group.	—

Countries

Netherlands

Outcome results